Answers are grounded in this paper and cite their sources.
Background Male infertility is a condition that is predominantly attributable to diminished spermatozoa characteristics and it presents with a wide spectrum of clinical manifestations (normozoospermia, asthenozoospermia, oligozoospermia, oligoasthenozoospermia, and necrozoospermia, teratozoospermia). The etiology underlying this condition is highly complex and heterogeneous. Currently, many clinical techniques are available to evaluate the characteristics of human spermatozoa. However, a novel technology capable of precisely detecting the molecular phenotype of human spermatozoa and enabling the etiological diagnosis of related male infertility is still lacking. Methods We established a new “molecular evaluation technology system for human spermatozoa characteristics” system (MEHS). MEHS includes the following: (1) a molecular antibody hybridization immunofluorescence assay; (2) quantitative analysis software for human spermatozoa functional molecule phenotypes in spermatozoa; and (3) a landmark atlas of the normal human spermatozoa functional molecule phenotypes. Through the analysis of 800 clinical samples exhibiting different manifestations, we judged the function and characteristics of spermatozoa. This allows the identification of male infertility target molecules caused by abnormal phenotypes (deficient, decreased, increased, shifted, or disabled) of spermatozoa functional molecules. Results We revealed that five target molecules presented abnormal phenotypes. The male infertility rates associated with different manifestations were 79.4% (the infertility rates associated with infertile normozoospermia were 44%, and that associated with oligozoospermia, oligoasthenozoospermia, and necrozoospermia was 95%). Conclusions MEHS can accurately detect the molecular phenotype in male infertility spermatozoa, identify the target molecules of male infertility, and be used for the detection of male infertility and its related causes. In addition, it can be detected that male infertility is caused by abnormal expression of one or more molecules. Accurate evaluation of spermatozoa characteristics via MEHS also assists clinicians in selecting optimal assisted reproductive technology protocols, thereby reducing unnecessary diagnostic procedures, treatment cycles, and patient costs. MEHS overcomes the limitations of the existing clinical human spermatozoa evaluation technologies and has potential scientific value and broad clinical applications.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: